×
About 19,396 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  7,889 results

Association of CTLA-4 (+49 A/G) polymorphism with susceptibility to autoimmune diseases...
https://doi.org/10.1016/j.intimp.2021.107617
International Immunopharmacology; Yu L, Shao M et. al.

Apr 18th, 2021 - In recent years, more and more studies have been focusing on the association between Cytotoxic T lymphocyte antigen-4 (CTLA-4) (+49 A/G) gene polymorphism and autoimmune diseases. However, the results of previous studies are still controversial. T...

Gut microbiota-microRNA interactions in ankylosing spondylitis.
https://doi.org/10.1016/j.autrev.2021.102827
Autoimmunity Reviews; Tavasolian F, Inman RD

Apr 17th, 2021 - Ankylosing spondylitis (AS) is a chronic autoimmune inflammatory disability that is part of the rheumatic disease group of spondyloarthropathies. AS commonly influences the joints of the axial skeleton. The contributions to AS pathogenesis of gene...

Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes enthese...
https://doi.org/10.1136/annrheumdis-2021-220002
Annals of the Rheumatic Diseases; Li Z, Chen S et. al.

Apr 16th, 2021 - The aim of this study was to identify the role of tenascin-C (TNC) in entheseal new bone formation and to explore the underlying molecular mechanism. Ligament tissue samples were obtained from patients with ankylosing spondylitis (AS) during surge...

The bone bridge significantly affects the decrease in bone mineral density measured wit...
https://doi.org/10.1371/journal.pone.0249578
PloS One; Lee SY, Song R et. al.

Apr 16th, 2021 - Ankylosing spondylitis (AS) has characteristics of spinal bone bridge and fusion. Although BMD reduction in AS may be presumed to be due to spinal inflammation, this study was designed to confirm whether immobilization of the spine due to syndesmo...

see more →

Guidelines  37 results

2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis ...
https://www.rheumatology.org/Portals/0/Files/AxialSpA-Guideline-2019.pdf
Ward MM,et al

Sep 30th, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). ankylosing spondylitis

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 22nd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
https://www.businesswire.com/news/home/20190723006033/en/FDA-Approves-Samsung-Bioepis-HADLIMA%E2%84%A2-adalimumab-bwwd

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthr...

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States
http://www.samsungbioepis.com/en/newsroom/detail/FDA-Approves-ETICOVO-Samsung-Bioepis-Second-Anti-TNF-Medicine.html

Apr 28th, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthri...

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guidelin...
https://www.rheumatology.org/Portals/0/Files/ACR-AAHKS-Perioperative-Management-Guideline.pdf
Goodman, S.,et al

Jul 31st, 2017 - This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid a.

see more →

Drugs  1,131 results see all →

Clinicaltrials.gov  9,517 results

Association of CTLA-4 (+49 A/G) polymorphism with susceptibility to autoimmune diseases...
https://doi.org/10.1016/j.intimp.2021.107617
International Immunopharmacology; Yu L, Shao M et. al.

Apr 18th, 2021 - In recent years, more and more studies have been focusing on the association between Cytotoxic T lymphocyte antigen-4 (CTLA-4) (+49 A/G) gene polymorphism and autoimmune diseases. However, the results of previous studies are still controversial. T...

Gut microbiota-microRNA interactions in ankylosing spondylitis.
https://doi.org/10.1016/j.autrev.2021.102827
Autoimmunity Reviews; Tavasolian F, Inman RD

Apr 17th, 2021 - Ankylosing spondylitis (AS) is a chronic autoimmune inflammatory disability that is part of the rheumatic disease group of spondyloarthropathies. AS commonly influences the joints of the axial skeleton. The contributions to AS pathogenesis of gene...

Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes enthese...
https://doi.org/10.1136/annrheumdis-2021-220002
Annals of the Rheumatic Diseases; Li Z, Chen S et. al.

Apr 16th, 2021 - The aim of this study was to identify the role of tenascin-C (TNC) in entheseal new bone formation and to explore the underlying molecular mechanism. Ligament tissue samples were obtained from patients with ankylosing spondylitis (AS) during surge...

The bone bridge significantly affects the decrease in bone mineral density measured wit...
https://doi.org/10.1371/journal.pone.0249578
PloS One; Lee SY, Song R et. al.

Apr 16th, 2021 - Ankylosing spondylitis (AS) has characteristics of spinal bone bridge and fusion. Although BMD reduction in AS may be presumed to be due to spinal inflammation, this study was designed to confirm whether immobilization of the spine due to syndesmo...

see more →

News  771 results

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
https://www.staging.medscape.com/viewarticle/940709

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
https://www.medscape.com/viewarticle/940709

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588_4

Jul 1st, 2020 - The age of onset of AS is usually from the late teens to 40 years. Onset in persons older than 50 years is unusual, although diagnosis of mild or asymptomatic disease may be made at a later age. Insidious onset of low back pain is the most common ...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588_1

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...

Fast Five Quiz: Ankylosing Spondylitis Signs and Symptoms
https://reference.medscape.com/viewarticle/932588

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...

see more →

Patient Education  51 results see all →